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Abstract
Background: An adult zebrafish heart possesses a high capacity of regeneration. However, it has been unclear whether and
how myocyte hyperplasia contributes to cardiac remodeling in response to biomechanical stress and whether myocyte
hypertrophy exists in the zebrafish. To address these questions, we characterized the zebrafish mutant tr265/tr265, whose
Band 3 mutation disrupts erythrocyte formation and results in anemia. Although Band 3 does not express and function in
the heart, the chronic anemia imposes a sequential biomechanical stress towards the heart.
Methodology/Principal Findings: Hearts of the tr265/tr265 Danio rerio mutant become larger than those of the sibling by
week 4 post fertilization and gradually exhibit characteristics of human cardiomyopathy, such as muscular disarray, re-
activated fetal gene expression, and severe arrhythmia. At the cellular level, we found both increased individual
cardiomyocyte size and increased myocyte proliferation can be detected in week 4 to week 12 tr265/tr265 fish. Interestingly,
all tr265/tr265 fish that survive after week-12 have many more cardiomyocytes of smaller size than those in the sibling,
suggesting that myocyte hyperplasia allows the long-term survival of these fish. We also show the cardiac hypertrophy
process can be recapitulated in wild-type fish using the anemia-inducing drug phenylhydrazine (PHZ).
Conclusions/Significance: The anemia-induced cardiac hypertrophy models reported here are the first adult zebrafish
cardiac hypertrophy models characterized. Unlike mammalian models, both cardiomyocyte hypertrophy and hyperplasia
contribute to the cardiac remodeling process in these models, thus allowing the effects of cardiomyocyte hyperplasia on
cardiac remodeling to be studied. However, since anemia can induce effects on the heart other than biomechanical, non-
anemic zebrafish cardiac hypertrophy models shall be generated and characterized.
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Introduction
Cardiac hypertrophy refers to the cardiac remodeling process in
response to a variety of intrinsic and extrinsic stimuli that stress the
heart [1]. Initially, the heart compensates for the stress through
increasing cardiac mass to normalize wall tension. However, if the
underlying stress is untreated, cardiac hypertrophy can lead to
sudden death or heart failure. The hallmarks of pathological
hypertrophy include enlargement of individual cardiomyocytes,
disarray of myofibrils, fibrosis in the extracellular matrix, re-
activation of fetal transcriptional programs, and decreased cardiac
function [2]. Due to the original dogma that cardiomyocytes in
mammals are post-mitotic cells that cannot proliferate, it was
believed that cardiac hypertrophy consists of hypertrophy of
cardiomyocytes and hyperplasia of other cell types in the heart,
such as fibroblasts. More recently, the discovery of cardiac stem
cells and the finding that cardiomyocytes have certain capacities to
proliferate challenged that concept and raised significant interest
in investigating the molecular mechanisms of myocyte hyperplasia
[3–5]. Furthermore, new research avenues have opened to harness
the proliferation capacity of cardiomyocytes as a potential
therapeutic strategy of heart failure [6].
Various model organisms have been utilized to understand the
molecular mechanisms of cardiac hypertrophy, each having its
advantages and disadvantages. Larger mammals, such as cats,
dogs, pigs, and primates, boast closer similarity of cardiac
physiology to that of humans, but genetic manipulation of them
is difficult [7]. Currently, smaller mammals (e.g., mice, rats, and
rabbits) are the major vertebrate models for molecular genetic
studies of cardiac hypertrophy [8]. To facilitate the identification
of novel genes and signaling pathways by forward genetics screen,
Drosophila has been adopted to study heart diseases [9]. However,
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accurately recapitulate a cardiac hypertrophic response.
Acclaimed as Drosophila in the vertebrate world, zebrafish can
easily be used in forward genetic screens [10,11]. Additionally, since
small molecules can be absorbed through their skin (and later gills),
zebrafish are ideal for screening small molecule libraries to discover
noveltherapeuticdrugs[12].Despite beinga well-recognized model
to study cardiogenesis [13], the zebrafish is an underutilized
organism for studying cardiac remodeling [14], possibly since
myocyte hypertrophy has not been reported in adult zebrafish.
Thus, the aimof thispaper is to characterizethe cardiac remodeling
process in an adult zebrafish model with a long term goal of
implementing the powerful genetic tools unique to the zebrafish to
uncover the molecular mechanisms of cardiac remodeling.
We investigated the cardiac remodeling process of tr265/tr265,
a zebrafish mutant identified from an ENU-mediated mutagenesis
screen. The mutation of tr265/tr265 was identified by means of
positional cloning to affect the erythroid-specific, transmembrane
protein Band 3 and prevent the erythrocytes from dividing,
resulting in apoptotic death of most of the erythrocytes [15]. The
chronic anemia imposes biomechanical stress to the heart and
results in cardiomegaly. Additionally, the low oxygen conditions
might promote the cardiomyocytes to undergo a metabolic switch
to a glucose-based metabolism, which uses less oxygen. Possibly
through this switch, the ischemic state could hinder normal fatty
acid oxidation, which has been shown to result in left ventricular
hypertrophy in humans and model organisms [16–19].
In this paper, we show that myocyte hypertrophy exists in
tr265/tr265 and, unlike in other model organisms, myocyte
hyperplasia also contributes significantly to the cardiac remodeling
process. Additionally, the longest-lived tr265/tr265 only have
myocyte hyperplasia, which suggests myocyte hyperplasia is
possibly a more effective cardiac remodeling mechanism to
support long-term survival of the fish under extrinsic stress.
Materials and Methods
Zebrafish Husbandry
Care and use of fish adhered to the IACUC protocol at Mayo
Clinic. At day four post fertilization, tr265/tr265 and the wild-type
siblings were manually sorted under a dissecting microscope based
on the amount of red blood cells observed in the tail region. Fifty
tr265/tr265 and fifty wild-type siblings were placed in separate
0.125-L rearing containers in the same 2.5-L tank until week four,
when they were transferred to separate 2.5-L tanks. Every ten
days, starting at fourteen days post fertilization, tr265/tr265 and
sibling densities were equalized. Water continually flowed into and
out of the tanks, except during live food meals. Fish were fed twice
a day everyday.
Ventricle Area to Body Length, Body Length, and Body
Mass
Dissected hearts were imaged next to a millimeter ruler with a
Nikon COOLPIX 8700 digital camera attached to a Leica MZ
FLI III microscope. AxioVision software (Carl Zeiss, Thornwood,
NY) was used to calculate the area of the ventricle from these
images in pixels squared. The number of pixels per mm was
calculated to convert the ventricle area into mm
2. To determine
ventricle area to body length, the ventricle area in mm
2 was
divided by body length (in mm). Body length was manually
measured with a millimeter ruler, from the tip of the mouth to the
body/caudal fin juncture. For measuring body mass, zebrafish
were anesthetized in a 0.16-mg/mL tricaine (Western Chemical,
Thornwood, NY) solution, semi-dried on paper towel, and
weighted on an AG204 DeltaRange scale (Mettler Toledo,
Columbus, OH).
Measurement of Hemoglobin Concentration
After anesthetizing a fish for three minutes in 0.16-mg/mL tricaine
(Western Chemical) solution, the gill region was dried with paper
towel, a Dumont #5 Biologie Inox forceps (Fine Science Tools,
Foster City, CA) was used to puncture the gill to induce bleeding, at
least 0.5 mL of blood was collected with a 1–5-mLc a l i b r a t e d
micropipet (Drummond Scientific Company, Foster City, CA)
containing approximately 0.5 mL 0.5 M pH 8 EDTA (Promega,
Madison, WI) to prevent aggregation, and the solution mixed in
200 mL (for siblings) or 20 mL( f o rtr265/tr265) Drabkin’s containing
Brij solution (Sigma, St. Louis, MO). Prior to blood collection, the
amount of EDTA in the micropipet was manually measured with a
mm ruler. After blood collection, the total volume was measured in
mm.ToconvertmmtomL, the number of mm to the 1-mLc a li b r a t e d
mark on the micropipet was determined. The blood was incubated at
room temperature for at least 15 minutes before measuring the
absorbance at 420 nm with a NanoDrop ND-1000 and V3.1.2
software (Thermo Scientific, Wilmington, DE). All absorbances fell
within the values used for the standard curve made with human
hemoglobin (Sigma) from a stock concentration of 0.8 mg/mL
human hemoglobin in Drabkin’s with Brij (Sigma). Final hemoglobin
concentration was calculated using the following equation: (absor-
bance/slope of the standard curve equation)/(volume of fish blood/
final diluted volume). Percent relative hemoglobin was calculated by
dividing the sibling value by the sibling value, and the mutant value
by the sibling value and multiplying by 100. The protocol was
modified from a previous version [20].
RT-PCR
Heart (washed in E3 water to remove blood cells) and blood
(washed in 1X PBS (Bio-Rad, Hercules, CA) and spun down at
2,000 RPM) from the wild-type zebrafish were froze in liquid
nitrogen and manually homogenized with a pistil and 18- and 27-
gauge needles (Tyco Healthcare/Kendall Mansfield, MA). An
RNeasy Mini Kit (Qiagen Valencia, CA) was used to purify the
mRNA, which was then treated with DNase I (Epicentre
Biotechnologies, Madison, WI) in NEBuffer 2 (New England
BioLabs, Ipswich, MA) to remove genomic DNA and reverse-
transcribed with SuperScript III First-Strand Synthesis System for
RT-PCR (Invitrogen, Carlsbad, CA). PCR was then conducted
with primers against Band 3 (forward: 59- ACTGGACCTG-
CAAAGCCAAG, reverse: 59- CCACAATGACGATCAGCCAC)
and the control, 18S (forward: 59- cacttgtccctctaagaagttgca, reverse:
59- ggttgattccgataacgaacga).
Western
Similar to the RT-PCR protocol, the heart (washed in E3 water
to remove blood cells) and blood (washed in 1X PBS (Bio-Rad)
and spun down at 2,000 RPM) from the wild-type sibling were
froze in liquid nitrogen and manually homogenized with a pistil
and 18- and 27-gauge needles (Tyco Healthcare/Kendall).
Samples were then lysed in SDS sample buffer (1M Tris-HCl
pH 6.8 (Fisher Scientific, Pittsburgh, PA), 10% glycerol (Acros
Organics, Geel, Belgium), 5% b-Mercaptoethanol (Sigma), 3.5%
SDS (Promega)) with protease inhibitor (Roche Applied Science,
Indianapolis, IN). To prevent AE1 aggregation, the blood was
denatured to 65uC for 10 minutes, while the heart was denatured
at 95uC. Proteins were separated via SDS-PAGE (Bio-Rad),
transferred to PVDF membranes (Bio-Rad), and blocked with 5%
(non-fat) dry milk. The primary antibodies against Band 3
(provided by Dr. Barry Paw) were diluted to 1:10,000 in 5%
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the secondary antibody.
H&E and Masson’s Staining
Dissected hearts fixed in 4% paraformaldehyde (Polysciences,
Warrington, PA) in 1X PBS (Bio-Rad) for two hours at room
temperature were dehydrated in methanol (Fisher Scientific),
embedded in JB4 (Polysciences), cross sectioned into four-micron
slices, and stained with hematoxylin and eosin (H&E) (Fisher
Scientific) or the Trichrome Stain Masson Kit (Sigma) by standard
techniques. Sections were analyzed using a Zeiss Axioplan 2
microscope (Carl Zeiss) and photographed with a Nikon COOL-
PIX 8700 digital camera.
Scanning and Transmission Electron Microscopy
Dissected hearts fixed in Trump’s solution overnight at 4uC
(plus a previous 1-hr incubation at room temperature for SEM
samples) were processed and imaged by the Mayo Clinic’s
Electron Microscopy Core Facility via a Hitachi S-4700 Field
Emission Scanning Electron Microscope or Philips CM10
Transmission Electron Microscope.
Immunostaining of Tissue Sections
Frozen sections 10–14-mm thick collected on Poly-Prep slides
(Sigma) were fixed with 4% paraformaldehyde (Polysciences) in
PBS (Bio-Rad), permeabilized with 0.1% Tween-20 (Bio-Rad) or
1% sodium dodecyl sulfate (Promega) in PBD (1% albumin bovine
serum (Sigma), 1% dimethyl sulfoxide (Mallinckrodt Baker,
Phillipsburg NJ), 1X PBS (Bio-Rad)), incubated with primary
antibody for two hours and secondary antibody for thirty minutes,
and imaged with a Zeiss Axioplan 2 microscope equipped with
ApoTome and AxioVision software (Carl Zeiss). Primary antibod-
ies included C9 (1:50 dilution, mouse, Novocastra, Newcastle,
UK), DsRed (1:50 dilution, Clontech, Mountain View, CA),
MEF2C (1:50 dilution, rabbit, Santa Cruz Biotechnology, Santa
Cruz, CA), PCNA (1:3000 dilution, mouse, Sigma), and ubiquitin
(1:50 dilution, mouse, Invitrogen). Secondary antibodies included
AlexFluor-conjugated anti-mouse or anti-rabbit IgG (1:50 dilution,
Invitrogen). To stain the nuclei, 1:10 of a 100 mg/mL Hoechst
33258 (Sigma) solution was added to the secondary antibody
solution.
Real-Time PCR
Three to five dissected week-6 and -16 hearts were frozen on dry
ice and homogenized with a mortar and pestle. RNA was extracted
using RNeasy Mini Kit (Qiagen). 1-mg total RNA was then reverse
transcribed by SuperScript III First-Strand Synthesis System for
RT-PCR (Invitrogen). To analyze the expression level of ANF, real-
time PCR was performed in a MyiQ Single-Color Real-Time PCR
Detection System (Bio-Rad) using iQ SYBR Green supermix (Bio-
Rad). 18S was used as an internal control to normalize ANF levels.
ANF (forward primer: 59- aagcaaaagcttgtctgg, reverse primer: 59-
actgtatccgcatattgcagc). 18S (forward primer: 59- cacttgtccctctaa-
gaagttgca, reverse primer: 59- ggttgattccgataacgaacga). Quantifica-
tion was done as detailed before [21].
Heart Rate
Heart rate was calculated by direct observation under a dissecting
microscope and counting the number of beats per minute.
Anesthetizingwith0.16-mg/mL tricaine(WesternChemical)solution
for one minute was required after day 21 post fertilization to keep the
fish still, although this may have depressed the heart rate. After week
five post fertilization, heart rate was obtained using ECG.
Red Blood Cell Flow Rate
For all time points, a single red blood cell was randomly chosen
in the tail region and timed with a millisecond stopwatch from two
arbitrary points (see Supplemental Figure S1). The distance
traveled by the red blood cell was measured via imaging the region
with a Nikon COOLPIX 8700 digital camera attached to a Leica
MZ FLI III microscope and using AxioVision software (Carl Zeiss)
to determine distance in pixels and number of pixels in 1 mm. For
rate, the time (in seconds) was divided by the distance (in mm).
Fish at day five post fertilization were not anesthetized. Week-6
fish were anesthetized in a 0.16-mg/mL tricaine (Western
Chemical) solution for two minutes and timed between minute
2.75 and three, while week-16 fish were anesthetized for 2.5
minutes and timed between minute 3.25 and 3.5.
Electrocardiography
Each fish anesthetized in a 0.16-mg/mL tricaine (Western
Chemical) solution for one minute was placed abdomen-up into a
slit damp sponge. A 29-gauge positive electrode (ADinstruments,
Colorado Springs, CO) connected to a BIOPAC ECG100C
(BIOPAC Systems, Goleta, CA) was gently pressed on the ventral
midline directly between the pectoral fins and the negative
electrode inserted through the caudal fin. The ECG signal was
recorded in one-second sweeps at an acquisition rate of 2,000
hertz with digital filtering at 0.5 hertz using AcqKnowledge 3.8.1
software (BIOPAC Systems).
Survival Curve
FiftyeachWTsiblingsand tr265/tr265 weresorted basedontheir
red blood cell level at day 5 and transferred to separate 0.125-L
rearing containers in the same 2.5-L tank. At week four, they were
transferred to separate 2.5-L tanks. Every ten days,starting at fifteen
days post fertilization, the number of each was counted. The fish
densities were equalized by placing the extra siblings in a separate
tank. Three different batches of the siblings and tr265/tr265 were
used for the experiment. To exclude the effect of normal die off that
occurs during the first two weeks post fertilization, values were
adjusted such that day 15 values represent 100% survival.
Cell Density and Proliferation Calculation
For cell density, a square of at least 5,000 mm
2 drawn using
AxioVision software (Carl Zeiss) per ventricle section (of 14-mm
thickness for DsRed hearts and 10-mm thickness of non-DsRed
hearts) per fish was analyzed. Cells in that square were counted
and divided by the square area to get cells per mm
2. Values from
the number of fish noted by ‘‘n’’ in the figures were averaged in
the graphs. For PCNA
+ MEF2
+ cell proliferation studies, the total
number of PCNA
+ MEF2
+ cells in each 10-mm ventricle section
per fish was divided by the estimated total number of MEF2
+ cells
in the ventricle section (based on calculating MEF2
+ cell density
and multiplying by the area of the ventricle section).
Cardiomyocyte Dissociation and Cell Size Quantification
Cells from dissected ventricles of Tg(cmlc2:nuDsRed) fish were
dissociated as described previously [22], resuspended in L-15
media containing 10% FBS (Invitrogen), placed in Lab-Tek eight-
well chambers (Thermo Fisher Scientific, Rochester, NY), and
cultured at 28.5uC for four hours. Merged images using phase
contrast and a 568-nm laser filter were captured with confocal
laser scanning microscopy (Zeiss LSM510; Carl Zeiss). About 20
to 30 dissociated cardiomyocytes per condition were randomly
chosen for cell area quantification using ImageJ software for each
of three independent experiments.
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Cardiomyocytes
Dissociated cells from dissected ventricles were cultured in L-15
media containing 10% FBS (Invitrogen) and 100 mM BrdU (Sigma)
for six days at 28.5uC in Lab-Tek eight-well chambers (Thermo
Fisher Scientific, Rochester, NY). On day three, a fresh batch of
BrdU-containing media was applied to the cells. To identify
cardiomyocytes, cells were fixed and stained for MEF2C (1:50
dilution, Santa Cruz Biotechnology) and Alexa Fluor 488 goat anti-
rabbit (1:200 dilution, Invitrogen), as previously described for tissue
sections. Next, cells were refixed for 10 minutes in 4% paraformal-
dehyde (Polysciences) in PBS (Bio-Rad) and stained according to
published protocol [23]. The primary antibody used was Monoclonal
Anti-BrdU from Sigma and Alexa Fluor 568 goat anti-mouse from
Invitrogen. Random areas of each chamber were imaged with a Zeiss
Axioplan 2 microscope (Carl Zeiss). At least 100 MEF2
+ cells per fish
were counted. Reported is the average number of BrdU
+MEF2
+(red
and green overlay) cells per total number of MEF2
+ (green) cells.
TUNEL Assay
Cryostat-sectioned hearts were stained with the In-Situ Cell
Death Detection Kit, Fluorescein (Roche Applied Science) similar
to manufacture’s protocol. For staining the nuclei, 1:10 of a
100 mg/mL Hoechst 33258 (Sigma) solution was added to the
reaction solution.
Phenylhydrazine Hydrochloride Treatment
In general, fish were treated for three weeks in containers
containing 2.5-mg/mL phenylhydrazine hydrochloride (PHZ, Sigma)
fish water solution. We found that higher dosages (e.g., 5 mg/mL)
significantly reduced the survival rate of the treated fish, while a lower
dosage (1.25 mg/mL) was not as effective in inducing cardiac
remodeling.ToacclimatetheyoungerfishtoPHZ,thefirsttreatment
was thirty minutes in 1.25-mg/mL PHZ solution. Every other day
thereafter, they were incubated for one hour in 2.5-mg/mL PHZ
solution. Survival was best for the year 1.5 fish when treated for
shorter and less frequent incubations. Thus, they were treated for 30
minutes once per three days in 2.5-mg/mL PHZ solution, instead of
once per two days. All groups were rinsed and washed for at least
thirty minutes in fish water after exposure to PHZ.
Statistical Methods
P values were calculated with a Student’s t-test, using mean and
standard error of the mean (SEM) values, and considered
significant if less than 0.05.
Results
Chronic anemia induces cardiac hypertrophy in tr265/
tr265
Paw et al. (2003) previously reported chronic anemia induces
cardiomegaly in tr265/tr265 zebrafish [15]. To further investigate
the cardiac remodeling process, we set up a system to separate
tr265/tr265 from their wild-type siblings at day 4 and maintained
the two groups at equal fish densities thereafter. Cardiomegaly is
evident in tr265/tr265 fish at week-6 and especially at week-16
(Figure 1A,A9). Dissection reveals the ventricle, atrium, and
outflow tract are larger (Figure 1B,B9). Quantification of the
ventricular area to body length (VA/BL) index indicates that the
heart is significantly larger by week 4 and approximately three
times larger at week 6 and 16 (Figure 1C). Supporting the
statement that this increased VA/BL is a consequence of chronic
anemia stress, we observe dramatically reduced number of red
blood cells at day four post fertilization and significantly decreased
hemoglobin concentration at week 16 (Figure 1D). Chronic
anemia did not seem to affect the general growth, however, as
reflected by the sustained body length and body weight at 6 weeks
and 16 weeks (Figure 1E,F). The increased body mass of week-16
tr265/tr265 is likely a result of the mutant’s sedentary behavior.
Despite their anemic condition, the pale tr265/tr265 (Figure 1A,A9)
can survive to adulthood and reach sexual maturity. For
verification that Band 3 is not expressed in the heart and thereby
directly affecting it, RT-PCR and western was conducted on
zebrafish blood and the heart (see Supplemental Figure S2).
We discovered the cardiac remodeling process in tr265/tr265
recapitulates perspectives of pathological hypertrophy in mammals.
H&E staining suggests myofibril organization is disrupted by
week 9 in tr265/tr265 (Figure 2A–A9). Muscular disarray was
confirmed by immunostaining of a-actinin, a Z-disc sarcomeric
protein (Figure 2B,B9), and by transmission electron microscopy
(Figure 2C,C9). Additionally, the papillary muscles appear disorga-
nized in scanning electron microscopy images of the week-16
mutant (Figure 2D,D9). mRNA levels of ANF, a fetal gene and
molecular marker of cardiomyocyte hypertrophy in mammals [24],
was more than 28 fold higher in the week-6 mutant. Interestingly,
ANF expression level is not significantly different at week 16
(Figure 2E). Nointerstitial fibrosis wasfound byMasson’sstaining at
either week 6 or 16 (data not shown). The above data suggests that
chronic anemia in zebrafish induces cardiac hypertrophy with
characteristics of pathological hypertrophy in mammals, as well as
some unique features that are different from mammals.
In tr265/tr265 fish, heart rate is initially faster on day 5 and 10
and slower on and after day 21 in the mutant (Figure 2F). This
switch of heart rate has been previously reported in zebrafish
treated with the anemia-inducing drug phenylhydrazine hydro-
chloride [25], which might reflect the adaptation process in either
the autonomous nerve or the pacemaker system that determines
the heart rate. Alternatively, it might indicate a switch of the
cardiac remodeling process from compensation to decompensa-
tion. Consistent with the heart rate data, the red blood cell flow
rate was faster on day 5 and slower on and after day 21 compared
to the sibling (Figure 2G). Altered heart function can be detected
in tr265/tr265 by electrocardiography (Figure 2H). ST is elevated
in some fish, which is consistent with the increased heart size.
Severe arrhythmia, such as missing a heart beat, can occasionally
be detected. Not surprisingly, tr265/tr265 has a high fatality rate,
with only 50% homozygous mutant fish surviving at week 7 and
less than 10% of mutants surviving at week 16 (Figure 2I).
Myocyte hypertrophy exists in zebrafish and contributes
to early stages of cardiac remodeling in tr265/tr265
At the cellular level, increased heart size can be accounted by either
increased individual cardiomyocyte size or increased cardiomyocyte
number. For testing the former hypothesis, we crossed tr265/tr265 fish
with Tg(cmlc2:nuDsRed), a transgenic fish line that labels nuclei of all
terminally-differentiated cardiomyocytes fluorescently red, to distin-
guish cardiomyocytes from non-cardiomyocytes (Figure 3A–B9). The
cardiomyocyte density in the ventricle of week-6 tr265/tr265 is
significantly lower than that in the wild-type sibling (6,0606321 vs.
7,8136292 cardiomyocytes/mm
2, Figure 3E), suggesting myocyte
hypertrophy. Non-cardiomyocyte density was the same in the week-6
sibling and tr265/tr265 (6,6016414 non-cardiomyocytes/mm
2 in the
sibling vs. 6,3446364 in tr265/tr265, Figure 3F). For confirmation of
myocyte hypertrophy, ventricle cardiomyocytes were dissociated,
cultured (Figure 3C–D9), and the surface area measured (Figure 3G).
Indeed, the surface area of the mutant’s cardiomyocytes is significantly
larger (23665 vs. 19069 mm
2 in the sibling) at week 6. Surprisingly,
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sibling (5,5636433 vs. 4,275693 cardiomyocytes/mm
2)( F i g u r e3 E ) ,
w h i l et h ec a r d i o m y o c y t es i z ei ss m a l l e r( 1 2 5 618 vs. 24964 mm
2 in
the sibling) (Figure 3D,D9,G). Additionally, week-16 tr265/tr265 has
an increased non-cardiomyocyte density compared to the sibling
(5,3876162 vs. 4,3396176 non-cardiomyocytes/mm
2)( F i g ur e3 F ) .I n
summary, the above data demonstrate cardiomyocyte hypertrophy
contributes to the initial stages of cardiac remodeling in tr265/tr265,
but not the later stages.
Myocyte hyperplasia contributes to all stages of cardiac
remodeling in tr265/tr265
The increased number of cardiomyocytes and smaller-sized
cardiomyocytes detected at week 16 imply that myocyte
hyperplasia is also being utilized by the fish to meet the challenge
of chronic anemia stress. To test this hypothesis, we identified and
then quantified proliferating cardiomyocyte-lineage cells by the
overlay of proliferating cell nuclear antigen (PCNA) antibody with
the MEF2 antibody (Figure 4A–B9). Indeed, the percent of
proliferating MEF2
+ cells is significantly increased in both week-6
(11.162.3% vs. 2.560.3% in the sibling) and week-16 tr265/tr265
fish (3.160.3% vs. 1.660.1% in the sibling) (Figure 4F). Another
marker of proliferation, BrdU, revealed cultured cardiomyocytes
proliferating (Figure 4C–C999) at levels observed in tissue sections
of week-6 (8.760.2% vs. 3.460.6% in the sibling) and week-16
(4.360.3% vs. 1.860.2% in the sibling) fish (Figure 4G).
Therefore, we conclude myocyte hyperplasia contributes to all
stages of cardiac remodeling in tr265/tr265. We also detected
significantly increased proliferation of non-cardiomyocytes in
mutants at both week 6 and week 16 (red cells in Figure 4A–B9).
There are two possible mechanisms of cardiomyocyte hyper-
plasia in zebrafish: the proliferation of terminally-differentiated
cardiomyocytes and the proliferation followed by the differentia-
tion of cardiac progenitor cells [26,27]. To examine the former
possibility, we conducted PCNA staining in offspring from
Tg(cmlc2:nuDsRed), which has all terminally-differentiated cardio-
myocyte nuclei labeled fluorescent red, crossed to tr265. PCNA
+
DsRed
+ cells were detected in the mutant fish (Figure 4D–D999),
suggesting that the proliferation of terminally-differentiated
cardiomyocytes is involved in the remodeling process. To examine
the latter possibility, we stained ventricle sections from
Tg(cmlc2:nuDsRed) fish crossed to tr265 with an anti-DsRed
antibody. It has previously been shown that newly differentiated
cardiomyocytes from cardiac progenitors cells can be identified by
their expression of unfolded DsRed protein in their cytoplasm
[26,27]. Indeed, we can detect this type of cell overlapping with
PCNA staining in mutant fish (Figure 4E–E999). Hence, prolifer-
Figure 1. Chronic anemia induces cardiomegaly in tr265/tr265 zebrafish. (A,A’) Pictures of the cardiomegaly in a week-16 (A’) tr265/tr265 and
normal appearance of (A) a sibling; arrowhead points to the heart region. (B,B’) Dissected hearts of (B) the sibling and (B’) tr265/tr265; A, atrium, V,
ventricle; bar=1 mm. (C) Ventricle area to fish length (VA/BL) index used as a measurement of the cardiomegaly for week-4, -6, and -16 hearts. (D)
Percent relative hemoglobin concentration at week 16. (E) Body length (in mm) at week 6 and 16. (F) Body mass (in grams) at week 6 and 16. (C–F)
mean6SEM; *=P,0.05. n=number of fish examined.
doi:10.1371/journal.pone.0006596.g001
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the cardiomyocyte hyperplasia in tr265/tr265.
Oncosis is the main form of cardiomyocyte death in
tr265/tr265 fish
In human patients with heart failure, three different types of cell
death have been detected, namely apoptosis, autophagy, and
oncosis [28,29]. We analyzed the contribution of these different
types of cell death to the cardiac remodeling process in tr265/tr265
from week 4 to 16. Increased oncosis of cardiomyocytes is
consistently detected in week 7 to 16 tr265/tr265 (Figure 5A,A9)a t
levels up to a few percent, while oncosis was mainly undetectable in
the sibling. Increased autophagic cardiomyocytes in tr265/tr265 can
alsobe detected by ubiquitinstainingfrom week 7 to 10,althoughat
lower levels than cardiomyocytes undergoing oncosis. For example,
Figure 2. Progressive cardiomyopathy is associated with tr265/tr265. (A,A’) H&E-staining revealing muscular disarray in week-9 (A’) tr265/tr265
ventricles, compared to the control (A); bar=50 mm. (B,B’) a-actinin antibody staining of week-12 ventricle sections (B, sibling, B’, tr265/tr265)( b a r=1 0mm)
and (C,C’) transmission electron microscopy of week-16 (C) sibling and (C’) tr265/tr265 ventricle sections (bar=1 mm) showing abnormal sarcomeres;
*=sarcomeres in C,C’. (D,D’) Disorganized papillary muscles in week-16(D’) tr265/tr265compared to(D) sibling viewed using scanningelectron microscopy;
bar=400 mm. (E) Increased atrial natriuretic factor (ANF), a fetal gene and cardiac hypertrophy marker, in week-6 and not week-16 tr265/tr265 hearts,
measured with real time PCR. (F) Changes in heart rate from day 5 to 42. (G) Red blood cell flow rate at day 4, week 6, and week 16, corresponding to the
results in G. Anesthesia was used to keep the fish still for timepoints after the dashed line. (H) Electrocardiograms of a sibling and two tr265/tr265 fish at
week20.(I)Survivalcurves(Kaplan-Meierrepresentation)ofthesibling(e)a n dtr265/tr265(&). (F–H) mean6SEM; *=P,0.05. n=number of fish examined.
doi:10.1371/journal.pone.0006596.g002
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compared to the barely detectable level in the sibling (Figure 5B,B9).
Although increased apoptosis in tr265/tr265 is also detected by
TUNEL staining from week 7 to 16, further examination by co-
staining with MEF2 revealed that only non-cardiomyocytes, but not
cells of cardiomyocyte-lineage, are affected (Figure 5C,C9).
Phenylhydrazine hydrochloride treatment of wild-type
zebrafish recapitulates the cardiac remodeling process of
tr265/tr265
Having characterized the cardiac remodeling process of the
tr265/tr265 mutant heart, we then aimed to develop a method for
inducing cardiac remodelingin wild-typefish,whichcanbe used for
future chemical and/or genetic screens. Aortic banding has been
routinely applied in larger animal models to induce cardiac
remodeling [30]. However, this microsurgery-based method cannot
be easily carried out in zebrafish, partially due to its small size. Since
fish live in the water, we reasoned small molecule treatment can be
exploited as an alternative approach. Phenylhydrazine hydrochlo-
ride (PHZ) is a small molecule that lyses red blood cells and has
previously been shown to result in anemia-induced cardiomegaly in
rainbow trout and rats [31,32]. We found treating wild-type
zebrafish in a 2.5-mg/mL PHZ solution induces anemia, evident by
the paleness in the gill region (Figure 6A–A9) and reduced relative
hemoglobin (Figure 6G) that are similar to those seen in tr265/tr265
(Figure 1A–A9and 1D ). After three weeks of treatment, the heart
becomes significantly larger than the control (Figure 6B–B9). The
VA/BL index increased in the week-6 (0.11660.007 vs.
0.05660.022 mm), week-13 (0.42760.023 vs. 0.27660.016 mm),
and year-1.5 treated fish (0.99660.135 vs. 0.50160.070 mm)
(Figure 6C). Based on body length measurements, treatment of
PHZ did not affect general growth (Figure 6D). Cardiomyocyte
density in year-1.5 treated fish, as revealed by MEF2 staining, is
lower in PHZ treated fish, suggesting myocyte hypertrophy
(Figure 6E). In addition, the increased percent of proliferating
MEF2
+ cells in the year-1.5 treated fish (6.861.5% vs. 2.060.3% in
the untreated) indicate activated myocyte hyperplasia (Figure 6F).
Thus, PHZtreatmentofwild-type fish induces a cardiac remodeling
response consisting of both myocyte hypertrophy and myocyte
hyperplasia similar to that of tr265/tr265.
Discussion
To exploit the value of zebrafish as a model organism for
studying cardiac remodeling and heart failure, we characterized
the chronic anemia zebrafish mutant tr265/tr265 (Figure 7).
Dramatically reduced concentration of red blood cells can be
detected in tr265/tr265 mutant fish at four days post fertilization
when primitive erythrocytes in embryos start to be replaced by
adult-type erythrocytes [33]. The red blood cell concentration
appears to be low throughout the whole lifespan of the mutant fish.
Under this consistent anemic challenge to the heart, the first sign
of myocyte hypertrophy can be detected at week 3 (data not
shown). Similarly, treatment of wild-type fish with PHZ for three
weeks can result in significantly increased heart size. A similar
cardiac hypertrophic response has been reported before in other
fish species, such as trout [31,34,35].
Figure 3. Myocyte hypertrophy contributes to early stages of cardiac remodeling in tr265/tr265. (A–B’) Images of cardiomyocytes (red
+
blue
+; arrow) and non-cardiomyocytes (blue
+ only; arrowhead) in week-6 and -16 (A, B) sibling and (A’,B’) tr265/tr265 ventricle sections from fish
outcrossed to Tg(cmlc2:nuDsRed) fish, whose terminally-differentiated cardiomyocyte nuclei are fluorescent red; blue is Hoechst-labeling of nuclei;
bar=10 mm. (C–D’) Dissociated ventricular cardiomyocytes cultured and imaged to reveal cell size and shape from week-6 and-16 (C,D) sibling and
(C’,D’) tr265/tr265 fish; bar=20 mm. (E) Cardiomyocyte and (F) non-cardiomyocyte density (cells/mm
2) from fish represented in A–B’. (G) Surface area
(in mm
2) of cultured cardiomyocytes, like the ones in C–D’. (E–G) mean6SEM; *=P,0.05. n=number of fish examined.
doi:10.1371/journal.pone.0006596.g003
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recapitulates perspectives of cardiomyopathy in mammals, such as
muscular disarray and re-activated fetal gene expression. Muscular
disarray appears at week 9 and is quite severe by week 16. ANF
expression is significantly higher in week-6 tr265/tr265 fish.
However, our current data cannot testify whether tr265/tr265 is
a model for heart failure, since a technique to measure ejection
fraction in adult zebrafish has not been established. Future possible
techniques include utilizing the transparent casper fish and novel
high-resolution and non-invasive technologies, such as high
frequency ultrasound and optical coherence tomography [36–38].
In this paper, we showed the existence of myocyte hypertrophy
in a zebrafish heart, thereby establishing this vertebrate animal as
an accessible model for studying cardiac hypertrophy. Surprising-
Figure 4. Myocyte hyperplasia contributes to all stages of cardiac remodeling in tr265/tr265. (A–B’) Overlay of proliferating cell nuclear
antigen (PCNA) antibody (red) with MEF2 antibody (green) in 10-mm sections of week-6 and -16 (A,B) sibling and (A’,B’) tr265/tr265 ventricles to show
proliferating cardiomyocyte-lineage cells (yellow overlay; arrow) and proliferation of other cells (red overlay; arrowhead); bar=50 mm. (C–C"’) Example
of recently divided cells of the cardiomyocyte lineage (green) detected with BrdU antibody (red); bar=10 mm. (D–D"’) Example of a proliferating
mature cardiomyocyte (encircled) from a tr265/tr265 Tg(cmlc2:nuDsRed) mutant fish expressing DsRed, MEF2, and PCNA in its nucleus; bar=10 mm.
(E–E"’) Proliferating cardiomyocytes (encircled) derived from a cardiac progenitor cell in tr265/tr265 Tg(cmlc2:nuDsRed) transgenic fish containing
unfolded DsRed in its cytoplasm and DsRed and PCNA in its nucleus. (F,G) Ratio of (F) PCNA
+ MEF2
+ cells over total MEF2
+ cells or (G) BrdU
+ MEF2
+
cells over total MEF2
+ cells in ventricles of week-6 and-16 sibling and tr265/tr265 fish, given as a percent; mean6SEM; *=P,0.05; n=number of fish
examined.
doi:10.1371/journal.pone.0006596.g004
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survive between week 4 and 12, but not in fish after week 12. One
possible explanation is that these hypertrophied cardiomyocytes
die and are replaced by new cardiomyocytes of smaller size. It is
likely that the cardiomyocytes die of oncosis and autophagy, but
not of apoptosis, since oncosis and autophagy of cardiomyocytes
were seen at elevated levels in tr265/tr265. Instead of death, the
hypertrophied cardiomyocytes possibly proliferate into normal- or
smaller-sized cardiomyocytes or shrink during the process of
pathogenesis. Of note, the increased oncosis detected in tr265/
tr265 probably is not a general consequence of cardiac remodeling
in zebrafish, since oncosis is a well-known consequence of the
hypoxic condition in animal models [39]
Poss et al. (2002) previously reported the zebrafish heart is able to
regenerate 20% of the ventricle without scarring [23]. In this paper,
we showed that myocyte hyperplasia is involved in all stages of
cardiac remodeling in tr265/tr265, with contribution from both
proliferation of cardiomyocytes and differentiation of cardiac
progenitor cells. The high capacity of myocyte proliferation is
different from mammals, which raises concerns regarding whether
cardiac remodeling in zebrafish accurately recapitulates all
pathophysiology in humans or mammalian models of cardiomyop-
athy. To fully address this concern, known signaling pathways in
human cardiac remodeling need to be examined in tr265/tr265 and
future zebrafish models [40]. On the other hand, the zebrafish
model offers the advantage of studying how myocyte hyperplasia
can be utilized as a remodeling strategy to meet the challenge of
biomechanical stress [6]. In fact, our observation suggests myocyte
hyperplasia might be a better remodeling strategy than myocyte
hypertrophy,sincethetr265/tr265thatsurvivethelongestonlyhave
myocyte hyperplasia. As future research directions, it will be
fascinating to investigate why zebrafish cardiomyocytes possess a
high capacity of proliferation, how myocyte hyperplasia contributes
to and affects the cardiac remodeling process, and whether we can
translate our knowledge learned from zebrafish to human patients.
This work establishes zebrafish as a new vertebrate animal that
complements existing animal models for studying cardiac hyper-
trophy. As the first adult zebrafish model of cardiac hypertrophy,
tr265/tr265 has some intrinsic limitations that need to be further
addressed. First, despite that we can eliminate the possibility the
Figure 5. Oncosis is the main form of cardiomyocyte death in tr265/tr265. (A–A’) Increased number of cardiomyocytes undergoing oncosis in
10-mm ventricle sections of (A’) tr265/tr265 compared to (A) the sibling detected by a C9 antibody (green) and a-actinin antibody (red;
cardiomyocytes); arrow points to a C9-positive cardiomyocyte; bar=10 mm. (B,B’) Few, but more, autophagic cardiomyocytes seen in (B’) tr265/tr265
vs. (B) the sibling with a ubiquitin antibody (green) and a-actinin antibody (red; cardiomyocytes); arrow points to an ubiquitin-positive
cardiomyocyte. (C,C’) Increased number of apoptotic non-cardiomyocytes (green overlay; arrowhead) in (C’) tr265/tr265, compared to (C) the sibling
detected with TUNEL (green); cardiomyocytes (nuclear DsRed); arrowheads point to the rare apoptosing cardiomyocytes (yellow overlay).
doi:10.1371/journal.pone.0006596.g005
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expression of Band 3 is restricted to red blood cells [15], it will be
difficult to separate the consequence of hemodynamic stress from
the hypoxic challenge to the heart. We acknowledge the possibility
that cardiac hypertrophy could be induced by other mechanisms
than anemic stress. To address this concern, we are currently
generating a transgenic Band 3 line for rescue experiments and
investigating whether cessation of the PHZ treatment can reverse
the cardiac hypertrophy. Second, anemia-induced cardiomyopathy
represents a high-output cardiac remodeling process, which is a
particular type of cardiac remodeling. Mimicking a volume
overload towards the heart, the underlying pathophysiology might
be different from aortic banding that imposes pressure overload.
Due to these limitations, additional zebrafish models of cardiac
hypertrophy need to be developed. For example, transgenic
technology that has been widely used in mouse to generate cardiac
hypertrophy models shall be adapted in zebrafish [8,30].
To further exploit the genetic potential of zebrafish as a disease
model, efficient screening strategies shall be developed to identify
novel mutants from mutagenesis screens that affect the cardiac
remodeling process. Towards this goal, the PHZ treatment
reported here provides a convenient assay for examining abnormal
cardiac remodeling responses in these mutants. As future research
directions, tr265/tr265 and other zebrafish models shall be utilized
in chemical screens to identify novel drugs targeting cardiac
hypertrophy, as well as to study the therapeutic value of promoting
cardiomyocyte hyperplasia.
Supporting Information
Figure S1 Starting and ending locations for the red blood cell
flow rate. Red blood cells were timed between the arrows shown in
the pictures of a (A) day-5 post-fertilization zebrafish at day 5, (B)
day-15 post-fertilization zebrafish at day 15 and 21, and (C) day 42
zebrafish caudal fin (fourth main ray from bottom) at day 42 and
week 16; bar=0.5 mm.
Found at: doi:10.1371/journal.pone.0006596.s001 (1.54 MB TIF)
Figure S2 Band 3 is not expressed in the zebrafish heart. (A,B)
(A) RT-PCR and (B) western of Band 3 expression in adult
zebrafish blood and lack thereof in the heart.
Found at: doi:10.1371/journal.pone.0006596.s002 (0.07 MB TIF)
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